Immunosuppression-mediated CKM

This session will review how commonly used immunosuppressive therapies impact metabolic health and kidney function after heart transplantation. Faculty will discuss practical, evidence-based strategies for managing cardiometabolic risk, including key safety and drug interaction considerations.

The session will also highlight current evidence gaps and opportunities to improve long-term cardiometabolic and kidney outcomes in transplant recipients.

Learning Objectives

• Describe how commonly used immunosuppressive therapies contribute to metabolic dysfunction and kidney injury.
• Apply evidence-based strategies for cardiometabolic therapy after transplant, including safety and drug interaction considerations.
• Identify key evidence gaps to improve cardiometabolic and kidney outcomes after heart transplantation.